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1. Introduction  
Drug delivery systems traditionally relied on passive diffusion mechanisms for targeting 
and releasing of therapeutically active molecules. The major problems associated with 
traditional delivery are poor specificity and dose-limited toxicity. Nanoparticles have found 
applicability in the development of novel drug delivery systems by easily overcoming 
toxicity problem. However, specificity of delivery has remained as a challenge. 
Developments in the methods of reaching to targeted tissue have lead to new and improved 
drug delivery platforms. Recently, active targeting has been incorporated by cell specific 
ligands such as antibodies, lectins, growth factor receptors. More recently, aptamers gained 
popularity in construction of novel actively targeted drug delivery systems (Ozalp et al., 
2011). Considerable proportions of aptamer-based delivery systems have been incorporated 
to a variety of nanomaterials in order to improve their specific targeting properties (Chen et 
al., 2011; Zhou et al., 2011). 
A successful therapy starts with diagnosis and then continues with application of right dose 
of therapeutic molecules to the site of diseased tissues or cells. Specific detection of cancer 
cells is essential for early diagnosis. Cancer cell types are diverse even within the same 
cancer category. Fast and accurate diagnosis requires multiple specific probes which can 
profile more than one type of cancer cell at a given time on the same sample. In that respect, 
cell-based aptamer selection can supply multiple biorecognition probe molecules for any 
desired number of target cell type. Early diagnosis of cancer relies largely on the sensitivity 
of detection methods. Nanoparticle-bioconjugates has been designed to develop high 
sensitivity sensors. In this chapter, we will summarize the recent developments in selecting 
cell specific aptamer selection and development of aptamer-targeted nanoparticles for 
medical applications. 
2. Selection of cell specific aptamers 
Aptamers are increasingly recognized as the future affinity molecules that can readily 
incorporated in nanodevices for medical applications. The recent progress in cell-specific 
selection methodology reconfirms this premise by supplying highly specific and high 
affinity aptamers for any type of diseased cells. Aptamers have generally been shown to 
have affinities and specificity that are comparable to antibodies. They have the advantage of 
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high stability at a variety of extreme physical conditions such as high temperature, high salt 
and ionic conditions with reversible denaturation properties (Deng et al., 2001; Liss et al., 
2002). Cell-specific apramers have been obtained by following two types of Selex procedure; 
by using the traditional approach i) against purified protein targets or by new approaches ii) 
against whole cells. Using purified proteins as targets has the advantage of technical control 
over assessments of enrichment during Selex procedure. However, the second approach has 
a clear advantage when the marker target is unknown.  
2.1 Aptamers selected for cell-specific proteins 
Aptamers are selected through a combinatorial procedure to identify short nucleic acid 
sequences that recognize specific targets. The procedure is based on a repeated cycle of 
affinity and separation. First target molecules are brought together with a library of nucleic 
acids. The usual number of members in such libraries is 1014-1018 random sequences. The 
library members will bind to target molecules if there is any recognition. The next step is the 
separation of bound and unbound library members through various chromatography 
techniques. It is commonly required to a cycle of 8 to 20 to enrich enough aptamer sequences 
which can be identified through sequencing since unspecific or common binder sequences 
will be favoured under the binding conditions. Detailed procedures on SELEX methods can 
be found elsewhere (Mayer, 2009). The simplest and direct way to obtain cell-specific 
aptamers is to isolate a marker protein that exists on the surface of target cell type and to use 
that protein as a target molecule in SELEX procedure. Many cell-specific aptamers have 
been selected using this strategy (Janas, 2011). The critical parameters for a successful 
selection are to identify cell-specific markers and to obtain the marker as pure starting 
material. Furthermore, the target that will be used in selection should be processed in such 
way that cell surface exposed regions of the molecule can be used during selection 
procedure. Several aptamers against cancer-related cells have been selected by using prufied 
proteins, including platelete-drived growth factor (PDGF) (Green et al., 1996), vascular 
endothelial growth factor (VEGF) (Ruckman et al., 1998), epidermal growth factor receptor 3 
(HER3) (Chen et al., 2003), transcription factor NFkB (Cassiday et al., 2001), tenascin-C 
(Hicke et al., 2001), prostate-specific membrane antigen (PSMA) (Lupold et al., 2002), and 
ErbB in breast cancer (Kim et al., 2011). 
The aptamer against ErbB is a typical selex procedure for selecting cell specific aptamers by 
using purified surface proteins. Epidermal growth factor receptor family (ErbB family) of 
receptor tyrosine kinases plays major roles in formation and progression of human cancers. 
Under normal physiological, ErbB receptors play important roles in some basic cellular 
processes such as proliferation, differentiation, motility and apoptosis. Upon ligand binding, 
ErbB receptors form homo- and heterodimers leading to the activation of their tyrosine 
kinase domain and subsequent autocatalytic phosphorylation of specific tyrosine residues in 
the cytoplasmic region. Amplification and overexpression of ErbB tyrosine kinases is 
associated with many types of solid tumors including breast, ovarian, head and neck, 
gastric, bladder, colorectal, salivary, renal, prostate and lung cancers (Salomon et al., 1995). 
ErbB receptors consist of an extracellular region, a single transmembrane region and a 
cytoplasmic tyrosine kinase domain (Cho et al., 2002). Thus, ErbB has been a target in cancer 
treatment. 2’-fluorine-modified RNA aptamers for the extracellular region of the receptor 
has been recently selected for their recognition of breast cancer cells (Kim and Jeong, 2011).  
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2.2 Aptamers selected for whole cells (cell-Selex) 
Cell specific aptamers can also be selected by using whole cells as target. Instead of selecting 
for a purified and defined target, aptamers can be selected by subtracting the background 
binding sequences after a selection cycle against the target. Whole-cell approach has been 
increasingly adapted more commonly for selecting new aptamers. Selection using live cell 
target means that the cell surface proteins will be in their native conformations by the right 
exposure as it would be in a real application. A panel of aptamers were selected for 
leukemia, myeloid leukemia, liver cancer, and lung cancer by using cell-Selex procedures. 
The aptamers selected by cell-selex resulted in high affinity specific aptamers, but more 
selection rounds compared to traditional selex were required (Fang et al., 2010). Figure 1 is a 
schematic representation of the cell-Selex approach. Complex targets such as tumor cells 
have been demonstrated to be compatible with the cell-Selex approach. The cell-selex 
procedure is easy to implement and faster than traditional Selex based methodologies. Most 
cell targets like cancer cells usually lack a clear marker protein which is highly specific for 
the type of application. Another important advantage of cell-selex is that the target  
 
Fig. 1. Steps in a typical cell-Selex procedure. A single-stanraded DNA library was first 
incubated with target cells. Nano-binding sequences were washed away and the sequences 
bound on target cells were eluted and isolated. The recovered sequences were incubated 
with control cells (negative cells) to eliminate the sequences which bind to common epitopes 
present on both target and control cell surfaces. This step ensures the enrichment of target 
cell specific aptamers. The sequences specifically binding to target cells were then amplified 
to obtain the pool for the next round of selex. The enrichment of target cell binding 
sequences were evaluated using a binding assay and the sequences from last round were 
cloned and sequenced. 
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molecules are at their optimum exposed form in vivo. A traditional selex procedure using 
purified marker protein can select aptamers recognizing any subregion of the protein, which 
can be cytoplasmic site, transmembrane regions or the regions of target proteins can be 
hidden when they are sitting in membrane. Therefore, cell-Selex allows a comparative 
strategy to identify differences at molecular levels. In this section, cell-Selex will be 
explained by using specific examples. However, recent reviews on cell-selex can be referred 
for a more detailed information (Guo et al., 2008; Fang and Tan, 2010).  
2.2.1 Aptamers targeting tumor cells 
Cancer cell types have been commonly a target for cell-Selex procedures in multiple 
example. An aptamer against RET receptors was selected by using cell line engineered for 
expressing RET tyrosine kinase receptors and background subtraction against non-
expressing cell line (Cerchia et al., 2005). Another advantage is that cell-selex can be carried 
out without knowing identity of surface proteins in a target cell. Moreover, it is possible to 
select a panel of aptamers recognizing surface proteins which does not exist in counter 
selection target. Cultured T cell acute lymphoblastic leucemia (CCRF-CEM) cells was used 
as target and human Burkitt’s lymphoma B-cells for counter-selex (Shangguan et al., 2006). 
Flow cytometry has been used to monitor the enrichment of aptamers after each cycle and 
several high affinity aptamers (Kd in nanomolar ranges) have been obtained with specific 
recognition properties for CCRF-CEM cells in a mixture of cells. The same procedure was 
also adapted to adherent liver tumor cells by first detaching the cells with a non-enzymatic 
solution (Shangguan et al., 2008). Six aptamers for Toledo and CCRF-CEM cell lines were 
tested for their ability to differentiate between real samples from leucemia patients 
(Shangguan et al., 2007). The results showed the ability of these aptamers to specifically 
detect molecular differences between patients. 
The identity of target on the surface of cell to which an aptamer are selected using cell-selex 
procedures can be determined by using post-Selex procedures. TD05 is an aptamer selected 
against Ramos cells by using cell-Selex methodology. The aptamer was determined to bind 
to Ramos cell through immunoglobulin heavy mu chain which is the heavy portion of the 
IgM protein. B-cell receptor complex are expressed in Ramos cells and IgM is the major 
component of this complex. The identification of identity of aptamer target was achieved by 
chemically modifying the aptamers with a photoactive uracil derivative for covalent binding 
of aptamer with their targets. Once aptamers are bound to targets covalently, they are 
isolated through magnetic extraction and the target protein was determined through mass 
spectroscopy techniques (Mallikaratchy et al., 2007).  
2.2.2 Aptamers targeting stem cells 
Aptamers can be used for recognition of any given cell population. The aptamer-based 
capture of circulating cells has been proposed for applications in regenerative medicine and 
tissue engineering. Mesechymal stem cells from whole bone marrow were used to generate 
aptamers for isolation purposes by local injection methods (Guo et al., 2006; Schaefer et al., 
2007). The aptamers recognizing osteoblasts were used to enrich them quickly and 
efficiently on titanium surfaces (Guo et al., 2007). Stents coated with capturing agents for 
endothelial proginator cells (EPC) from circulating blood stream have been proposed to 
achieve fast enthelialization of the implanted stents and hence acceleration of the healing 
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process of vascular tissue (Aoki et al., 2005; Szmitko et al., 2006). The capturing techniques 
was demonstrated with antibodies, peptides and aptamers (Wendel et al., 2010). In one 
example, aptamers for high affinity for circulating porcine EPC was selected for EPC fishing 
(Hoffmann et al., 2008). The application of EPC capture stents is a promising therapeutic 
approach to rapidly create an in vivo endothelialization of artificial surfaces. However, 
antibody based application has the problems due to the heterogeneity of EPC populations 
and the poor definition of EPC surface molecules. Therefore, the success of this approach 
depends on a better characterization and understanding of EPC biology and aptamers can 
offer the needed biorecognition molecules for the desired cell population for using in fishing 
approach as a successful therapy. Aptamer-based biological coatings which mimic the self 
healing potential of the patients' stem cell pool for vascular wall regeneration offer 
excitating new therapy strategies (Wendel, Avci-Adali et al., 2010). Aptamers recognizing 
EPC cells have also been demonstrated as one of the cell sources useful in cardiac stem cell 
therapy because they can contribute to neoangiogenesis and regenerate infarcted 
myocardium. This new therapeutic method based on aptamers was demonstrated that the 
transplantation of aptamer-isolated EPCs after myocardial infarction improves angiogenesis 
(Sobolewska et al., 2010).  
2.2.3 Aptamers targeting microbial cells 
Another group of cell specific aptamers has been selected for microbial cells. Aptamer-based 
detection of pathogens is an effective diagnostic tool in food industry and medicine. 
Aptamers targeting viruses, protozoa, or bacteria have been selected for biosensor 
development (Karkkainen et al., 2011). A subtype of human influenza virus has been 
detected by aptamers demonstrating the feasibility of using aptamers in detecting 
pathogenic viruses in contaminated environmental and food matrixes (Gopinath et al., 2006). 
African trypanosomes are a specific class of protozoan organisms responsible for the 
parasitic disease sleeping sickness. Aptamers specific for the African trypanosomes were 
reported for a surface protein located within the flagellar pocket of the parasite (Hoffmann, 
Paul et al., 2008) and for a surface glycoprotein of the Trypnosoma brucei subsp. Brucei 
(Lorger et al., 2003). Aptamers can target against some of the surface proteins of micro-
organism, and the growth of the bacteria can be inhibited. The only example of therapeutic 
aptamer with antimicrobial properties has been demonstrated with virulent Mycobacterium 
tuberculosis (Chen et al., 2007).  
3. Drug delivering nanoparticles 
Nanoparticles have many potential applications in medicine ranging from bioimaging to 
drug delivery. They have been synthesized from a variety of materials that could be 
degradable or stable, depending on the type of application. Although developing new types 
of materials is an exciting research area for future applications, pharmaceutical applications 
mostly rely on materials with history in human use to reduce the risks involved (Grama et 
al., 2011). Exposing malignant tumour cells that migrate to adjacent tissues or circulate in 
bloodstream is critical for early detection and effective therapy. Passive delivery refers to 
nanoparticles loaded with drugs are administered into body without any specific targeting. 
The improvement over conventional methods has been obtained by adjusting the release 
properties of the nanoparticles by selecting special materials during the synthesis of 
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particles. On the other hand, increasing surface area to volume ratio for a delivery vehicle 
has huge benefits in improving solubility of biologically available drugs. Simple entrapment 
of bioactives inside nanoparticles has been shown to result in significantly higher 
bioavailability compared to their conventional administration methods (Mittal et al., 2007). 
Designed formulations for adjusting release rate are pursued with success in multiple 
examples (Cozar-Bernal et al., 2011; Tsai et al., 2011). For example, PLGA nanoparticles are 
biocompatible, synthesized at different grades, and safe (used for long time with humans). 
The release, degradation and elimination rates of PLGA nanopartiles can be tailored to 
desired parameters. On the other hand, nanoparticles can be functionalized for targetd 
delivery. Active delivery refers to incorporating a specific targeting mechanism in drug-
loaded nanoparticle delivery vehicle.  
Aptamers have been considered as potentially interesting targeting molecules for 
nanoparticles. The main reason is that conjugation of aptamers to other molecules or 
nanoparticles is a straight-forward procedure and the attachment does not change the 
affinity or specificity properties of aptamers. Early diagnosis can be achieved by systems of 
aptamer-nanoparticle conjugates because high affinity aptamers can be obtained for tumour 
cells. There have been many approaches in for detection of tumor cells that is based on 
mechanical forces, immunohistochemistry, magnetic cell sorting, and flow cytometry. The 
detection based on affinity interactions is expected to yield higher efficiency and sensitivity. 
Antibody based affinity sensors are often found to be high levels of cross-reactivity. There 
are also technical challenges in crosslinking antibodies on the surface of nanodevices (Wan 
et al., 2010). Thus, there is an increasing recognition for aptamers as promising utility in 
cancer diagnosis. 
Three critical steps should be considered in designing an efficient aptamer-targeted 
nanoparticle drug therapy; targeting, internalization and degredation of the targeted cells by 
release of loaded drugs (Fig. 2). 
4. Aptamer-based targeting of nanoparticles 
Aptamers are biorecognition molecules with multiple properties that make them attractive 
targeting elements. Aptamers can bind to their targets with high affinity and specificity, 
comparable to antibodies. The in vitro selection methodology is the major advantage 
ensuring availability for any desired application. Moreover, nucleic acids have unique 
properties that are frequently exploited in construction of nanomachines . A combination of 
all of the above-mentioned properties makes aptamers a desirable targeting agent for novel 
nanoparticle-based drug delivery systems. Recent developments in cell based Selex 
technology have raised expectations for medical applications required targeting of whole 
living cells. Two major medical applications of aptamer-based targeting of nanoparticles are 
bioimaging and drug delivery. 
4.1 Bioimaging applications 
In vivo imaging is a valuable tool in clinical diagnostics and critical to develop ultrasensitive 
methods (Soontornworajit et al., 2011). Many techniques of imaging from whole organism 
(e.g. NMR) to specific molecular imaging (e.g. Fluorescence) are available and they are 
envisioned to be on the focus for developing cancer diagnosis, drug delivery, guided stem  
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Fig. 2. A scheme of targeted Nanoparticle drug delivery. Drugs are loaded inside the 
nanoparticles that are conjugated to antigen-binding recognition element which bind 
specifically to antigen expressing cells. The nanoparticles are rapidly internalized once 
bound on the surface of diseased cells. The drugs encapsulated in the nanoparticles are 
released inside the cells and destroys the integrity of cells. 
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cell therapies, imaging of gene expression to monitor disease development, gene therapy, 
image guided surgery (Hahn et al., 2011). Nanoparticles for bioimaging should fullfill 
several requirements; being dispersable and stable in vivo, low non-specific binding, and 
high selectivity for their targets. There are four types of nanoparticles that are commonly 
used in conjugation with aptamers for biological imaging applications; 1) gold 
nanoparticles, 2) quantum dots, 3) silica nanoparticles and 4) magnetic nanoparticles. 
A nonoparticle imaging and drug delivery system has been developed by conjugating A10 
aptamers to quantum dots (Bagalkot et al., 2007). Fig. 3 shows a schematic representation of 
aptamer-quantum dot bioconjugate for drug delivery and imaging of delivered drugs as 
reported. The chemotherapeutic drug doxorubicin is an nucleic acid intercalating molecules. 
A bi-FRET system was prepared by attaching PSMA aptamers on the surface of quantum 
dot nanoparticles and doxorubicin was immobilized on the aptamer molecules by 
intercalation. Doxorubucin is a fluorescent molecule, but quenched by gold and nucleic 
acids. Therefore, the system targets the doxorubicin in non-fluorescent form to the surface of 
prostate cell. When the drug carrier system is internalized by the cells, doxorubicin is free 
from aptamer and quantum dots and become fluorescent, signalling the delivery of drug 
into cancer cells. Another example of quantum dot-aptamer conjugates in bioimaging was to 
identify and isolate subpopulations of tumor cells with high specificity. In another example, 
quantum dots were conjugated to liver hepatoma cell line aptamers through a sterptavidin-
biotin binding. The quantum-dor-aptamer complexes were shown to specifically recognize 
MEAR cells specifically comapered to HeLa cells and BNL cells (Zhang et al., 2010).  
Aptamer conjugated magnetic nanoparticles are proposed for in vivo isolation of specific 
cells and also for magnetic resonance imaging (MRI) techniques. Aptamer-magnetic 
nanoparticles were used to isolate mesenchymal stem cells and endothelian progenitor cells 
for isolating “ready to transplant” cells as promising methods (Schaefer, Wiskirchen et al., 
2007; Sobolewska, Avci-Adali et al., 2010). Prostate cancer specific A10 aptamers conjugated 
to magnetic nanoparticles were used as magnetic resonance contrast agents for lower 
toxicity and stronger binding properties (Wang et al., 2008). 
Silica nanoparticles can be readily loaded with fluorescent molecules and highly 
fluorescent, stable nanoparticles can be obtained. They are stable, hydrophilic, 
biocompatible, chemically inert. Another advantage is that organic dyes can be 
encapsulated in the silica with advantages of less photobleaching. Furthermore, aptamers 
can be easily attached to the surface of silica. Up to 100 fold increase in sensitivity has 
been obtained in flow cytometry applications with dye-doped silica nanopartiles (Estevez 
et al., 2009). In an effort to develop sensitive monitoring of multiple cancer cell lines, three 
different aptamers were conjugated to fluorescent doped silica nanoparticles (Chen et al., 
2009). Human acute lymphoblastic leukemia cells specific aptamer, Ramos cells specific 
aptamer, and Toledo cells specific aptamer were used in developing multiple assays. 
Nanomaterials are often used for multivalent ligand binding purposes to increase the 
signal and sometimes enhance the binding affinity. For example, gold-silver nanorods 
were used as a platform for multiple aptamer immobilization. Up to 80 aptamers could be 
attached to rods for obtaining 26-fold higher affinity and 300-fold higher fluorescence 
(Huang et al., 2008).  
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Fig. 3. Represantation of nanoparticle-aptamer based bi-FRET system for drug delivery and 
bioimaging. Doxorubicin is a fluophore and intercalates into nucleic acids. The fluorescence 
of doxorubicin is quenched by both gold and the aptamers. The quantum dot-aptamer-
doxorubicin complex is targeted to tumor cells and internalized, and doxorubicin is released 
inside the cell, removing the quenching. The system targets the drug into diseased cells and 
the release of the drug can be monitored once it is delivered into desired site. 
4.2 Aptamer-targeted drug delivery in nanoparticles 
Aptamer-targeted delivery of drugs by using nanoparticles has similar advantages to 
bioimaging applications. The nanoparticles are specifically targeted to cell-types that are 
required for therapeutic molecules to act on. The drug delivery through nanoparticle 
encapsulation provides a vehicle for controlling the precise level and location of drugs in the 
body, reducing unwanted toxicity to healthy cells, lowering the doses needed. For example, 
drug encapsulated nanoparticles with a controlled release system can be developed and 
targeting to diseased cells can maximize the therapeutic efficacy and reduce undesired side 
effects (Langer, 2001).  
Proof-of-concept nanoparticle-based vehicles have been developed for targeted drug 
delivery to prostate cancer cell surfaces with high specificity and efficiency. Once bound to 
tumor antigens, nanoparticles will be internalized through endocytosis. The toxic cargo of 
the nanoparticles will be released inside the tumour cells. Targeted delivery achieves a safe 
vehicle to destroy selectively the cancer cells. During the research of similar proof-of-
concept research, teh nanoparticles commonly loaded with fleorescent molecules to study 
the pathways, the success of targeting and release rate of cargo. 
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4.2.1 Prostate cancer as model system 
Aptamers potentially can direct nanoparticles to cancer cell antigens present on the surface 
of tumour cells. Therapeutic nanoparticles are specifically designed to encapsulate drugs 
and release the drugs in preregulated and predetermined way. Prostate cancer has been the 
first model disease for aptamer mediated nanoparticle targeting. Prostate specific membrane 
antigen protein (PMSA) is a well-known marker antigen which is over expressed on 
tumorigenic prostatic epithelial cells. Two RNA aptamer binding to extracellular portions of 
PSMA has been selected and shown to adhere selectively to PMSA positive cells (Lupold, 
Hicke et al., 2002). Later, an in vitro analysis device was developed in order to study the 
specific targeting properties of PMSA aptamer-nanoparticle conjugates (Farokhzad et al., 
2005). The device was a model of prostate cancer targeting using a microfluidic cell under 
physiological fluid conditions similar to microvasculature. In this experiments, the 
microchannels were seeded with protate cancer epithelial cells expressing PMSA or non-
expressing cells lines. Pegylated poly(lactic acid) (PLA) particles conjugated to A10 PMSA 
aptamer were tested for various experimental parameters mimicking the intraveneous 
administration of nanoparticles. The results confirmed that the particles were rapidly 
internalized into PMSA positive cells. The optimized aptamer-nanoparticle vehicle loaded 
with the chemotherapeutic drug docetaxel was later shown to reduce tumors upon injection 
into mice (Farokhzad et al., 2006; Cheng et al., 2007). This example was the first targeted 
delivery using nanoparticle-aptamer bioconjugates. The drug delivery was achieved to be 
highly specific for PMSA positive cells under in vivo contions. The same system of 
nanoparticle-aptamer bioconjugate was shown to deliver cisplatin drug to prostate cancer 
cells by improving simultaneously both tolerance and efficacy in mice (Kolishetti et al., 
2010). 
Nanomaterials for drug delivery are required to be stable and biocompatible. Current 
technology can supply materials that are capable of partially fulfilling these properties. 
Thus, combinations of surface coatings with complementary properties are proposed for 
developing better functioning delivery systems. In one example, gold nanorods were 
encapsulated within thin and uniform layer of silica shell for enhanced stability and and a 
layer of PEG was used for biocompatibility. The composite nanoparticles were 
functionalized with PSMA aptamers and tested for their ability to target the nanopartciles to 
prostate cancer cells (Hu et al., 2011). 
4.2.2 Other examples 
Vasculature targeted delivery is an attractive strategy due to the phenotypic changes on the 
endothelial cell surface associated with pathological conditions such as inflammation and 
angiogenesis. E-selectin is expressed in inflammed vaculator in advanced tumors and it can 
be used as marker for pathological vasculator. A high affinity thio-backbone modified 
aptamers against E-selectin were recently selected by using recombinant-expressed protein 
(Mann et al., 2010). E-selection aptamers were incorporated in liposomes, the targeting 
efficiency and pharmokinetic properties of delivery were investigated (Mann et al., 2011). 
CCRF-CEM recognizing aptamers (sgc8c) were conjugated to doxorubucin-doped silica 
nanoparticles and delivered leukemia cells with high specificity and efficiency (He et al., 
2011).  
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4.2.3 Aptamer-based gating systems 
The efficacy of drug therapy is determined by two parameters; efficient targeting of drug to 
the diseased site and the controlled release of the drug. The potential of aptamer-based 
targeting have been demonstrated in multiple examples as presented in above sections in 
order to improve specific delivery properties of drug carrying nanoparticles. The bioactive 
molecules in the nanoparticles were released with traditional mechanism such as 
internalization, endocytosis and degradation of nanomaterial once the nanoparticles attach 
to the surface of diseased cell surface. However, aptamers can be also exploited in 
controlling the release of drugs from nanoparticles. Two recent reports indicate to future 
potential of aptamers as targeting and gating agents in nanoparticle-based drug delivery. A 
snap-top type molecular gate using aptamer-gold nanoparticle complex to control the 
release of cargo of silica nanoparticles was shown to respond to aptamer target for stimuli-
responsive release (Zhu et al., 2011). In another report, switchable control of the gating in 
nanocarriers through aptamers was shown to control the release rate of active molecules in 
response to taptamer target stimuli (Ozalp et al., 2011).  
5. Conclusion 
Nanoparticle-aptamer bioconjugates provide exciting prospects in medical nanotechnology 
for future disease treatments. The advancements in nanomaterial field together with cell-
Selex procedures offer the controlled release polymer systems conjugated to aptamers 
tweaked to the any target diseased cell. Therefore, it is possible to produce a diverse range 
of specific and selective nanoparticle-aptamer bioconjugates. Drug delivery vehicles can 
improve the therapy of a myriad of important human diseases by using aptamer-
nanoparticle bioconjugates. Aptamer-based targeting has already achieved progress in 
demonstrating the usability nanoparticle-aptamer bioconjugate systems to improve 
nanomaterial drug delivery vehicles in model animals. Next critical step for realization of 
potentials of bioconjugated nanoparticles will be clinical realization studies in near future. It 
is worth to indicate that with aptamers being in principle available for any kind of target 
(e.g., small metabolites, proteins, lipids, ions), it can be anticipated a straightforward 
transfer of proof-of-concept results to other applications when developing efficient drug-
delivery systems. Finally, aptamer-based molecular gating of nanoparticle cargo can bring 
new approaches in drug delivery field by combining targeting and controlled release in the 
same mechanism.  
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